Search hospitals > Oregon > Portland
OHSU Knight Cancer Institute
Claim this profilePortland, Oregon 97239
Global Leader in T-Lymphoblastic Leukemia/Lymphoma
Global Leader in Breast Cancer
Conducts research for Leukemia
Conducts research for Skin Cancer
Conducts research for Lymphoma
427 reported clinical trials
52 medical researchers
Summary
OHSU Knight Cancer Institute is a medical facility located in Portland, Oregon. This center is recognized for care of T-Lymphoblastic Leukemia/Lymphoma, Breast Cancer, Leukemia, Skin Cancer, Lymphoma and other specialties. OHSU Knight Cancer Institute is involved with conducting 427 clinical trials across 436 conditions. There are 52 research doctors associated with this hospital, such as Lara Davis, MD, Zahi Mitri, Shivaani Kummar, MD, and Jeremy P. Cetnar.Area of expertise
1T-Lymphoblastic Leukemia/Lymphoma
Global LeaderStage IV
BCR-ABL1 positive
t(9;22) translocation positive
2Breast Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
Lara Davis, MDOHSU Knight Cancer Institute5 years of reported clinical research
Studies Soft Tissue Sarcoma
Studies Cancer
16 reported clinical trials
46 drugs studied
Zahi MitriOHSU Knight Cancer Institute1 year of reported clinical research
Expert in Breast Cancer
Studies Breast cancer
15 reported clinical trials
37 drugs studied
Shivaani Kummar, MDOregon Health and Science University1 year of reported clinical research
Expert in Solid Tumors
Studies Uterine Tumors
15 reported clinical trials
24 drugs studied
Jeremy P. CetnarOregon Health and Science University6 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
11 reported clinical trials
23 drugs studied
Clinical Trials running at OHSU Knight Cancer Institute
Pancreatic Cancer
Prostate Cancer
Skin Cancer
Acute Myeloid Leukemia
Cancer
Colorectal Cancer
T-Lymphoblastic Leukemia/Lymphoma
Breast Cancer
Stomach Cancer
Leukemia
Calaspargase + Cobimetinib
for Pancreatic Cancer
This phase I trial tests the safety, side effects, and best dose of calaspargase pegol-mknl in combination with cobimetinib in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Cobimetinib attacks a protein called MEK that has been known to stimulate cells that promote the growth of cancer cells in the body. Calaspargase pegol-mknl is an enzyme that converts the amino acid L-asparagine into aspartic acid and ammonia. Many types of cancer cell rely on the amino acid L-asparagine, and depleting this amino acid with calaspargase pegol-mknl starves cancer cells of this nutrient. Attacking the MEK protein with cobimetinib is thought to further prevent cancer cells from using this amino acid, causing them to die. Giving calaspargase pegol-mknl in combination with cobimetinib may help control the disease in patients with pancreatic cancer.
Recruiting1 award Phase 117 criteria
Precision Medicine Approach
for Cancer
This phase II trial tests the how well a precision medicine approach (serial measurements of molecular and architectural response to therapy \[SMMART\])-adaptive clinical treatment \[ACT\]) works in treating patients with sarcoma, prostate, breast, ovarian or pancreatic cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). SMMART testing uses genetic and protein tests to learn how cancer changes and to understand what drugs may work against a person's cancer or why drugs stop working. These test results are reviewed by a group of physicians and scientists during a SMMART tumor board who then recommend precision therapy.
Recruiting1 award Phase 24 criteria
CAR T-cell Therapy
for Stomach & Pancreatic Cancer
This trial is testing a new treatment using modified immune cells to target and kill cancer cells in patients with advanced stomach, esophagus, or pancreatic cancer. The treatment focuses on cancers that have a specific protein. The treatment targets a specific protein found on certain cancer cells and has shown promise in previous studies for treating advanced stomach and esophagus cancers. The study aims to find the best dose for future use.
Recruiting1 award Phase 1
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at OHSU Knight Cancer Institute?
OHSU Knight Cancer Institute is a medical facility located in Portland, Oregon. This center is recognized for care of T-Lymphoblastic Leukemia/Lymphoma, Breast Cancer, Leukemia, Skin Cancer, Lymphoma and other specialties. OHSU Knight Cancer Institute is involved with conducting 427 clinical trials across 436 conditions. There are 52 research doctors associated with this hospital, such as Lara Davis, MD, Zahi Mitri, Shivaani Kummar, MD, and Jeremy P. Cetnar.
Where is OHSU Knight Cancer Institute located?
The OHSU Knight Cancer Institute is situated on the South Waterfront campus in Portland, OR, located at 3181 S W Jackson Park Rd, Portland, OR 97239.
Who should I call to ask about financial aid or insurance network?
**OHSU Knight Cancer Institute Financial Assistance:**
- For assistance with medical care costs at OHSU, Hillsboro Medical Center, and Adventist Health Portland, contact 503-494-8551 (Mon-Fri, 8 a.m. to 4:30 p.m. PT).
- Eligibility includes those without health insurance, insufficient health insurance, or qualifying for state/federal assistance.
**OHSU Knight Cancer Institute Insurance Department:**
- For billing and insurance inquiries, call 866-617-6855.
- This contact serves all OHSU Health hospitals and clinics for general billing and insurance questions, excluding some professional charges.
What insurance does OHSU Knight Cancer Institute accept?
The OHSU Knight Cancer Institute accepts a wide range of insurance plans, including but not limited to Aetna, CareOregon, Cigna, Health Net, Humana, Kaiser Permanente, Moda, Molina Healthcare, PacificSource, Providence Health Plan, Regence BlueCross BlueShield, and TriWest HealthCare Alliance. They also accept original Medicare, known as traditional Medicare. It's important to verify coverage with your insurance provider before receiving care.
What awards or recognition has OHSU Knight Cancer Institute received?
The OHSU Knight Cancer Institute, located in Portland, Oregon, is a National Cancer Institute-designated Comprehensive Cancer Center. This prestigious recognition places it among the nation's elite for laboratory and clinical research, community service, and multidisciplinary scientific research. It is also an active member of global cancer organizations and networks, positioning it at the forefront of cancer research and care.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.